

Supplementary Table S1. Summary of TRAEs

TRAE	mCSCC (N=78)
Any, n (%)	56 (71.8)
Grade 3	8 (10.3)
Grade 4	0
Grade 5	0
Immune-related TRAE, n (%)	15 (19.2)
Grade ≥ 3	1 (1.3)
Serious, n (%)	3 (3.8)
Occurring in $\geq 5\%$ of participants, n (%)	
Fatigue	10 (12.8)
Rash	8 (10.3)
Diarrhea	5 (6.4)
Pruritus	5 (6.4)
Hypothyroidism	4 (5.1)
Infusion-related reaction	4 (5.1)
Lipase increased	4 (5.1)

mCSCC, metastatic cutaneous squamous cell carcinoma; TRAE, treatment-related adverse event.